Home >> About

News & Events

NEW YORK, June 01, 2017 (GLOBE NEWSWIRE) -- Mid Atlantic Bio Angels (MABA) announces today that Recensa Therapeutics (http://www.recensatherapeutics.com), which is developing a topical psoriasis treatment designed to reduce oxidative stress, was named “Best in Show” by the audience and “Most Fundable” by the investor panel at MABA's 1st Pitch Life Science event held on May 25, 2017 at Rockefeller University in New York City.

May 31st, 2017: Dr Magid Abou-Gharbia chairs Pharma Outsourcing Best Practices Panel at 2017 ChemSpec Europe Meeting at the Munich Trade Fair Center, Germany.

 

Dr.Benjamin E Blass and Dr. Daniel J Canney received grant from the Crohn's & Colitis Foundation to study the role of the 5-HT7 receptor in inflammatory bowel disease (IBD).  The three year, $347,490 program entitled “Novel Therapies for the Treatment of Ulcerative Colitis: 5-HT7 Antagonists" will also include Dr. Waliul Khan from McMaster University. Dr. Khan is a leading expert in IBD animal models and pharmacology.

Magid Abou-Gharbia presents keynote address at the 2017 CPhI Connect Conference. His lecture highlighted the issues that face the pharmaceutical industry and possible opportunities to address industry challenges in a changing regulatory and political environment.

Philadelphia, PA February 2, 2017 - A startup emerging from Temple University's School of Pharmacy builds on the work of two of its medicinal chemists and could potentially change the way inflammatory bowel disease is treated.  The company, Praeventix, is advancing a discovery made by the School of Pharmacy’s Daniel Canney and Benjamin Blass of the Moulder Center for Drug Discovery Research.

Praeventix LLC, a biotech start-up company based on science developed at the Moulder Center was awarded "Best University Startups 2016” by the National Council of Entrepreneurial Tech Transfer at its University Startups Demo Day event on September 20, 2016.

Philadelphia, PA May 26, 2016 - Dr. Salim Merali has been awarded an NIH RO3 grant entitled: “Activators of Nrf2 Translation in Alzheimer’s Disease “ in the amount of $156,000 for a period of two years. Dr. Carlos Barrero, another Moulder Centerr faculty member, is a Co-Investigator on this grant.

Philadelphia, PA December 14, 2015 - NTSAD congratulates Marlene Jacobson, PhD, awardee of the 2015 Million Dollar Bike Ride grant made on behalf of Team NTSAD for her proposal entitled "Patient-Derived Phenotypic Assay to Discover Treatments for Tay-Sachs Disease."

Philadelphia, PA September 17, 2015 - Dr. Benjamin E Blass and Dr. Daniel J Canney were awarded an NIH STTR grant in partnership with Cognition Therapeutics of Pittsburgh, PA. The 1 year, $298,527 program entitled "Novel sigma-2 receptor modulators for the treatment of cognitive dysfunction" will allow then to expand their effort to develop novel therapies for the treatment of Alzheimer's disease.

Philadelphia, PA September 9th, 2015: Dr. Salim Merali (Moulder Center for Drug Discovery Research), Dr. Gunther Boden (Temple University Medical School) and their colleagues demonstrated that excessive caloric intake causes rapid onset of oxidative stress, GLUT4 carbonylation, and insulin resistance in healthy men.  Their findings were published in the internationally recognized journal Science Translational Medicine.

http://nypost.com/2015/09/14/the-american-diet-will-make-you-sick-in-jus...

https://www.yahoo.com/health/this-is-what-happened-when-1254722010800182...

http://www.cbsnews.com/news/these-men-ate-6000-calories-a-day-for-science/

Pages

Temple University

Moulder Center for Drug Discovery Research

Temple University School of Pharmacy
3307 N Broad Street
Philadelphia, PA 19140